Description

A patient who survives childhood cancer may be at increased risk for leukemia secondary to therapy with alkylating agents. Tucker et al developed an alkylator score to quantify a patient's exposure to alkylating agents. The authors are from multiple hospitals in North America and Europe participating in the Late Effects Study Group.


 

The first step is to identify each alkylating agent (including procarbazine) that the patient received.

 

The second step was to tally the total dose for each alkylating agent received and to standardize as mg per square meter BSA).

 

The third step was to determine the total dose distribution for each alkylating agent and to divide it into thirds (lower, middle, upper). If the distribution of doses shows a Gausian distribution then the middle third would be the mean +/- 0.41 SD.

 

An assumption would be that the dosage ranges have been standardized and are not exceeded.

Distribution

Points

not given

0

lower third of doses

1

middle third of doses

2

upper third of doses

3

 

total alkylator score =

= SUM(points for all alkylating agents received)

 

Interpretation:

• minimum alkylator score: 0

• maximum alkylator score: 12 (assumes exposure to a maximum of 4 alkylating agents)

• The higher the score the greater the risk of developing leukemia.

• The risk of developing leukemia was impacted by the total radiation dose.

• The risk of developing leukemia was impacted by exposure to the vinca alkaloids and to doxorubicin.

 

Alkylator Score

Aprroximate Relative Risk for Leukemia (Adjusted for Radiation)

<= 2

1.0 (low)

3 or 4

8.0 (moderate)

5 or 6

18 (high)

>= 7

23 (high)

from Table 3 page 462.

 


To read more or access our algorithms and calculators, please log in or register.